Feltner, Douglas E.
Novartis Gene Therapies, Inc. (United States)
6 papers on CoChat
Most cited papers
- Verified
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
Day, J. W., Finkel, R. S., Chiriboga, C. A., Connolly, A. M., Crawford, T. O., Darras, B. T., Iannaccone, S. T., Kuntz, N. L., Peña, L. D. M., Shieh, P. B., et al. (2021) · The Lancet Neurology
Neurogenetic and Muscular Disorders ResearchVirus-based gene therapy research
Cited by 494
- Verified
Psychometric evaluation of a visual analog scale for the assessment of anxiety
Williams, V. S., Morlock, R. J., & Feltner, D. (2010) · Health and Quality of Life Outcomes
Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychometric Methodologies and Testing
Cited by 287
- Verified
A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH 1 Antagonist) in the Treatment of Major Depression
Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T. (2008) · American Journal of Psychiatry
Treatment of Major DepressionStress Responses and Cortisol
Cited by 254
- Verified
Efficacy of the Novel Anxiolytic Pregabalin in Social Anxiety Disorder: A Placebo-Controlled, Multicenter Study
Pande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R. T., Pollack, M., Stein, M. B., Lydiard, R. B., Futterer, R., Robinson, P., Slomkowski, M., et al. (2004) · Journal of Clinical Psychopharmacology
Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTreatment of Major Depression
Cited by 227
- Verified
AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort
Al-Zaidy, S. A., Kolb, S. J., Lowes, L., Alfano, L. N., Shell, R., Church, K. R., Nagendran, S., Sproule, D. M., Feltner, D. E., Wells, C., et al. (2019) · Journal of Neuromuscular Diseases
Neurogenetic and Muscular Disorders ResearchLysosomal Storage Disorders Research
Cited by 185
- Verified
Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy
Lowes, L. P., Alfano, L. N., Arnold, W. D., Shell, R., Prior, T. W., McColly, M., Lehman, K. J., Church, K., Sproule, D. M., Nagendran, S., et al. (2019) · Pediatric Neurology
Neurogenetic and Muscular Disorders ResearchVirus-based gene therapy research
Cited by 179
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free